Mexican women with family history more likely to have triple-negative breast cancer vs. other types
the ONA take:
According to new findings presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved in San Antonio, Texas, researchers from the University of California San Diego Moores Cancer Center in La Jolla, California, have found that patients of Mexican descent with breast cancer who had a family history of breast or ovarian cancer were nearly two times as likely to have triple negative breast cancer than other types of breast cancer.
For the study, researchers identified 1,150 women of Mexican descent with breast cancer, 14.9% of whom reported having a first-degree relative with breast or ovarian cancer. They found that women with a first-degree relative who had one of those cancers were nearly twice as likely to be diagnosed with triple-negative breast cancer compared with other types of breast cancer.
The findings suggest that there will be implications in regard to prevention, screening, and treatment of women of Mexican descent with a family history of breast or ovarian cancer. Triple negative breast cancer is often associated with poor outcomes because it lacks the targets for common treatments.
Now, the researchers are investigating whether BRCA mutations are the cause of the association between family history and triple-negative breast cancer that was observed in this study.
Patients of Mexican descent with breast cancer and family history nearly two times as likely to have triple negative breast cancer.
Breast cancer patients of Mexican descent who had a family history of breast or ovarian cancer were almost twice as likely to have triple-negative breast cancer than other subtypes of breast cancer, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Nov. 9–12.
"Triple-negative breast cancer is one of the worst breast cancer subtypes in terms of outcomes," said Maria Elena Martinez, PhD, the Sam M. Walton endowed chair for cancer research and a professor in the Department of Family and Preventive Medicine at the University of California San Diego Moores Cancer Center in La Jolla.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|